Where We Are Now with LEN for PrEP

This timeline tracks the regulatory approval process for lenacapavir (LEN) for HIV prevention from late 2024 through early 2026. Key milestones include FDA Priority Review status, FDA approval in June 2025, expected subsequent approvals from European regulators and WHO, and Global Fund and PEPFAR commitment to roll out LEN to three million people over the next three years.

AVAC Infographics for INTEREST 2026

For those presenting at INTEREST (as well as anyone interested in tracking the field), AVAC’s latest infographics on HIV R&D and the delivery pipeline, the current landscape of prevention options are available in an easy-to-use slide format—including lenacapavir for HIV PrEP (LEN) volume commitments, and the impact of US funding cuts with new data from PEPFAR. We hope these are useful for presentations and discussions at the conference and beyond.

We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.

The Power of bNAbs: A new frontier in HIV cure research

In this video, from the Series of Jojo, viewers are introduced to broadly neutralizing antibodies (bNAbs) and how they might one day be used in finding a functional cure for HIV.

Avac Event

Launching STI Advocacy Hubs: National Agendas from Kenya, South Africa & Zimbabwe

Join AVAC and partners for the launch of STI Advocacy Hubs and the introduction of new country-led advocacy agendas from Kenya, South Africa, and Zimbabwe. This webinar will highlight the key challenges shaping STI prevention, diagnostics, and care in each country, and outline priority actions to strengthen national responses. Speakers from partner organizations will share how these agendas aim to drive policy change and improve access to STI prevention tools.

Moderator: Alison Footman

Speakers:

  • Teodora Wi, former Team Lead for Sexually Transmitted Infections at the WHO
  • Lori Newman, Gates Foundation
  • Felix Mogaka and Mercy Nyakowa (Kenya)
  • Alex de Voux and Mandisa Mdingi (South Africa)
  • Chido Diva Chikwari, Chido Moira Majaha, and Constancia Mavodza (Zimbabwe)

Avac Event

Conference on Retroviruses and Opportunistic Infections (CROI 2026)

The annual Conference on Retroviruses and Opportunistic Infections (CROI) took place February 22–25, 2026, in Denver, Colorado.

Check out AVAC’s Highlights from the Meeting

AVAC Infographics

AVAC’s visuals for presentations and discussions were seen across the conference. Access them here in an easy-to-use slide format.

Community Breakfast Clubs

Each day during CROI, AVAC, EATG, Fiocruz, TAG, and other partners hosted virtual webinars called Community Breakfast Clubs featuring researchers and advocates breaking down important prevention, treatment and cure science presented at CROI and the implications for the field.

AVAC Infographics for CROI 2026

Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.

AVAC Year in Review 2025

2025 underscored the vital role that AVAC plays in the global health ecosystem, and why our work and our partnerships have never been more essential.

This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization. Read the PDF below or view as a webpage.

An Overview of Lenacapavir for PrEP Trials

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.

One year ago, we sued the US Government…

Today marks one year since AVAC and the Journalism Development Network worked with the Public Citizen Litigation Group to sue the US President, the State Department, the US Agency for International Development (USAID), and others, seeking emergency relief from a sweeping freeze on foreign assistance issued by the incoming administration that abruptly halted life-saving global health and development programs. A parallel case was brought by Global Health Council and partners and assigned to the same District Court judge, underscoring the broad concern across the global health community.

Twelve months later, these cases have come to symbolize a much larger question: whether the executive branch can override Congress’s constitutional authority over federal spending and dismantle decades of bipartisan foreign policy with the stroke of a pen, and whether the courts and Congress will fulfill their responsibilities to serve as checks on unbridled executive power.

The past year has laid bare the real-world consequences of unchecked executive action, threatening lives, destabilizing global partnerships, and undermining the United States’ credibility as a reliable partner. 

An early ruling in AVAC’s case successfully unlocked nearly $2 billion in US government payments for work already completed, affirming that the executive branch cannot refuse to spend money appropriated by Congress. But over the course of 2025, appeals by the administration, ultimately backed by the US Supreme Court, ran down the clock on $4 billion in already-appropriated funds for the 2025 fiscal year, allowing them to expire.  

While the Supreme Court’s ruling did not resolve the underlying constitutional questions, the decision was narrow and the Court left open the opportunity for further argument on the merit of the questions involved. In November 2025, a joint statement to the District Court requested to pause the cases, awaiting the outcome of other relevant court decisions.   

The AVAC and GHC cases remain active, but lawsuits alone cannot restore what was lost—or undo the long-term harm caused by the sudden dismantling of global health systems. 

The actions by this administration demand more than concern. This moment demands public accountability, sustained Congressional oversight, and durable legislative safeguards. Global health and equity require champions willing to fight for lives and livelihoods, and for what’s right. We cannot accept this as the new normal, and we must insist that Congressional authority, democratic governance, and the lives they protect still matter. 

If you’d like to support AVAC in its continued work, please consider making a donation, https://donatenow.networkforgood.org/donate-avac.

Change in PrEP Initiations from 2024 to 2025 in Five Countries

Between the period January-September 2024 to January-September 2025, PrEP initiations fell between 13% and 66% in selected high-volume PrEP countries where ministries of health (MoH) were able to provide data. Among the five countries depicted, four saw significant decline in PrEP uptake. All four relied on PEPFAR PrEP programs and were disrupted by stop work orders (SWO).